Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma

Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic Asthma

(2020) Joanne E. Kavanagh et al.   CHEST

Asthma exacerbations on benralizumab are largely non‐eosinophilic

(2020) Sophie M. Poznanski et al.   ALLERGY

Normalisation of MRI ventilation heterogeneity in severe asthma by dupilumab

(2019) Sarah Svenningsen et al.   THORAX

Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma

(2018) Roma Sehmi et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma

(2016) R. Sehmi et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

(2010) Roland Kolbeck et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY